Ensysce Biosciences | D: Filing D
Ensysce Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Lincoln Park Capital Fund, LLC(3.792%),Lincoln Park Capital, LLC(3.792%), etc.
Ensysce Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Bob G. Gower(5.7%)
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities-Director GOWER BOB G
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities-Director GOWER BOB G
Ensysce Biosciences | D: Filing D
Ensysce Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HG Vora Capital Management, LLC(2.1%)
Ensysce Biosciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-CVI Investments, Inc.(4.9%),Heights Capital Management, Inc.(4.9%)
Ensysce Biosciences | SC 13G: Statement of acquisition of beneficial ownership by individuals-Lincoln Park Capital Fund, LLC(9.99%),Lincoln Park Capital, LLC(9.99%), etc.
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | SC 13G: Statement of acquisition of beneficial ownership by individuals-CVI Investments, Inc.(7.8%),Heights Capital Management, Inc.(7.8%)
Ensysce Biosciences | D: Filing D
Ensysce Biosciences | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Matthews Lane Capital Partners LLC(7.9%),Daniel B. Silvers(7.9%), etc.
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
Ensysce Biosciences | 4: Statement of changes in beneficial ownership of securities
No Data